查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1197291

吸入一氧化氮市场 - 增长、趋势、COVID-19 影响和预测 (2023-2028)

Inhaled Nitric Oxide Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 110 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

在预测期内，可吸入一氧化氮市场预计将以 4.6% 左右的复合年增长率增长。

主要亮点

  • 推动市场增长的某些因素包括呼吸道疾病和其他相关疾病的患病率上升以及持续的研发活动。
  • 吸入的一氧化氮 (iNO) 是一种肺血管扩张剂，在调节血管肌张力方面起着重要作用。 自从上个世纪认识到一氧化氮 (NO) 是一种重要的内皮衍生血管扩张剂分子以来，NO 研究领域已经扩展到包括生物医学研究的多个领域。 现在众所周知，NO 是体内的重要信使。
  • 最近的数据表明，吸入一氧化氮可能适用于多种疾病。 例如，研究表明吸入 NO 是一种安全有效的试剂，可用于测量肺血管床的血管舒张能力。
  • 目前的证据还表明，iNO 可改善妊娠 35 週以上的婴儿的氧气输送并减少死亡或出生时需要体外膜氧合的综合结果。 由于这些因素，市场有望在预测期内实现稳定增长。

吸入一氧化氮市场趋势

哮喘和慢性阻塞性肺病在吸入一氧化氮市场表现出良好的增长

美国过敏、哮喘和免疫学协会 (AAAI) 表示，2016 年，美国约有 8.3% 的儿童被发现患有哮喘。 发现 9.2% 的男孩和 7.4% 的女孩患哮喘病的可能性略高于女孩。

儿童哮喘患病率从 2001 年的 8.7% 上升到 2010 年的 9.4%，然后下降到 2016 年的 8.3%。 儘管并非所有变化都具有统计学意义，但亚人口统计研究表明，墨西哥/墨西哥裔美国儿童除外，他们的哮喘患病率从 2001 年的 5.1% 增加到 2016 年的 6.5% 在该群体中观察到类似的概况。

根据疾病预防控制中心的数据，从 2013 年到 2017 年，美国 18 岁及以上从不吸烟的工作成年人中估计有 240 万 (2.2%) 患有慢性阻塞性肺病。 在从不吸烟者中，COPD 患病率最高的是信息行业 (3.3%)、采矿业 (3.1%) 以及办公室和行政支持人员 (3.3%)。 女性的 COPD 患病率高于男性。

此外，根据慢性阻塞性肺疾病全球倡议（GOLD）发布的2019年报告，全球有6500万人患有慢性阻塞性肺疾病（COPD），每年有300万人死亡，位居第三。死亡原因。

北美主导吸入一氧化氮市场

根据 Matthew Diamond 于 2020 年发表的一篇文章，美国 ARDS 的估计发病率为 64.2-78.9 例/100,000 人年。 25% 的 ARDS 病例最初被归类为轻度，75% 的病例被归类为中度或重度。 然而，三分之一的轻度疾病患者会发展为中度或重度疾病。

哮喘的患病率在医疗保健和社会援助行业的工人中也最高，8.8% 的工人在调查时报告患有哮喘。

此外，教育服务业以8.2%的比例位居第二。 因此，预计在预测期内，呼吸系统疾病患病率的增加将有助于北美占据较大的市场份额。

吸入式一氧化氮市场竞争对手分析

市场竞争激烈，参与者众多。 2020 年 2 月，Bellerophon Therapeutics 公布了其用于治疗肺纤维化相关肺动脉高压（PH-PF）的 INOpulse（脉衝吸入一氧化氮）递送系统的 2b 期研究的阳性顶线数据。宣布。 Air Liquide Healthcare、Mallinckrodt、Matheson Tri-Gas、Merck KGaA、Novotelis、NuMed Plus、Perma Pure LLC 和 Praxair Technology 等公司占据了很大的市场份额。

其他福利。

  • Excel 格式的市场预测 (ME) 表
  • 三个月的分析师支持

内容

第一章介绍

  • 调查结果
  • 调查假设
  • 本次调查的范围

第二章研究方法论

第 3 章执行摘要

第四章市场动态

  • 市场概览
  • 市场驱动因素
    • 呼吸道疾病和其他相关疾病的患病率上升
    • 正在进行的研究和开发活动
  • 市场製约因素
    • 每个地区都有严格的应用标准
  • 波特的五力分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分

  • 按产品类型
    • 煤气
    • 交付系统
  • 通过申请
    • 新生儿呼吸治疗
    • 支气管哮喘/COPD
    • 急性呼吸窘迫综合征
    • 疟疾药物
    • 肺结核治疗
    • 其他用途
  • 按地区
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东
      • 海湾合作委员会
      • 南非
      • 其他中东地区
    • 南美洲
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章竞争格局

  • 公司简介
    • Air Liquide Healthcare
    • Mallinckrodt
    • Matheson Tri-Gas Inc.
    • Merck KGaA
    • Novoteris
    • Nu-Med Plus
    • Perma Pure LLC
    • Praxair Technology Inc.

第7章 市场机会今后动向

简介目录
Product Code: 68861

The inhaled nitric oxide market is anticipated to register a CAGR of nearly 4.6%, during the forecast period.

Key Highlights

  • Certain factors that are driving the market growth include rising prevalence of respiratory and other associated diseases and ongoing research and development activities.
  • Inhaled nitric oxide (iNO) is a pulmonary vasodilator that plays a major role in regulating vascular muscle tone. Since the acknowledgment of nitric oxide (NO) as a key endothelial-derived vasodilator molecule in the last century, the field of NO research has expanded to encompass several areas of biomedical research. At present, it is well established that NO is an important signaling molecule throughout the body.
  • Recent data suggest that inhaled NO can be applied in a wide variety of diseases. For instance, studies indicate that inhaled NO is a safe and effective agent to determine the vasodilatory capacity of the pulmonary vascular bed.
  • Current evidence also shows that iNO improves oxygenation and decreases the combined outcome of death or necessity for extracorporeal membrane oxygenation in infants of more than 35 weeks' gestational age at birth. Owing to all the aforementioned factors, the market is expected to observe steady growth over the forecast period.

Inhaled Nitric Oxide Market Trends

Asthma and COPD Shows Lucrative Growth in the Inhaled Nitric Oxide Market

* The American Academy of Allergy Asthma and Immunology (AAAI) states that, in 2016, approximately 8.3% of children in the United States was found to have asthma. Boys were to some extent more likely to have asthma than girls at a rate of 9.2% and 7.4%, respectively.

* Asthma incidence among children increased from 8.7% in 2001 to 9.4% in 2010, and then declined to 8.3% in 2016. Although not all changes were statistically noteworthy, a similar outline was observed among subdemographic groups studied, except the Mexican/Mexican-American children, among whom asthma prevalence increased from 5.1% in 2001 to 6.5% in 2016.

* According to the CDC, during 2013-2017, an estimated 2.4 million (2.2%) US working adults aged more than 18 years who never smoked had COPD. The highest COPD prevalences among persons who never smoked were in the information (3.3%) and mining (3.1%) industries and office and administrative support occupation workers (3.3%). Women had higher COPD prevalences than did men.

* Moreover, as per the 2019 report published by the Global Initiative for Chronic Obstructive Lung Disease (GOLD), 65 million people suffer from chronic obstructive pulmonary disease (COPD) and 3 million die from it each year, making it the third leading cause of death worldwide.

North America Dominates the Inhaled Nitric Oxide Market

* According to a 2020 article by Matthew Diamond, estimates of the incidence of ARDS in the United States range from 64.2 to 78.9 cases/100,000 person-years. 25% of ARDS cases are initially classified as mild and 75% as moderate or severe. However, a third of the mild cases go on to progress to moderate or severe disease.

* In addition, asthma prevalence was highest among workers in the healthcare and social assistance industry, with 8.8% of workers stating that they had asthma at the time of the survey.

* The source also states that participants in the educational services industry reported the second-highest rate of asthma at 8.2%. Hence, the growing prevalence of respiratory diseases is expected to contribute to the significant market share of North America over the forecast period.

Inhaled Nitric Oxide Market Competitor Analysis

The market is competitive and consists of a number of players. In February 2020, Bellerophon Therapeutics announced positive topline data from the phase 2b study of INOpulse (pulsed, inhaled nitric oxide) delivery system for the treatment of pulmonary hypertension associated with pulmonary fibrosis (PH-PF). Companies like Air Liquide Healthcare, Mallinckrodt, Matheson Tri-Gas Inc., Merck KGaA, Novoteris, Nu-Med Plus, Perma Pure LLC, Praxair Technology Inc., hold the substantial market share in the market.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence of Respiratory and Other Associated Diseases
    • 4.2.2 Ongoing Research and Development Activities
  • 4.3 Market Restraints
    • 4.3.1 Strict Apllication Norms across Various Regions
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product Type
    • 5.1.1 Gas
    • 5.1.2 Delivery Systems
  • 5.2 By Application
    • 5.2.1 Neonatal Respiratory Treatment
    • 5.2.2 Asthma and COPD
    • 5.2.3 Acute Respiratory Distress Syndrome
    • 5.2.4 Malaria Treatment
    • 5.2.5 Tuberculosis Treatment
    • 5.2.6 Other Applications
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Air Liquide Healthcare
    • 6.1.2 Mallinckrodt
    • 6.1.3 Matheson Tri-Gas Inc.
    • 6.1.4 Merck KGaA
    • 6.1.5 Novoteris
    • 6.1.6 Nu-Med Plus
    • 6.1.7 Perma Pure LLC
    • 6.1.8 Praxair Technology Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS